DIA 48th Annual Meeting
Click here to go to the previous page
Doping Abuse of Medicines in Sport: The Challenge to Industry and Regulators
Track
:
Track 14: Clinical Safety and Pharmacovigilance
Program Code:
390
Date:
Wednesday, June 27, 2012
Time:
3:30 PM to 5:00 PM
EST
CHAIR
:
Barbara Leishman, F. Hoffmann-La Roche Ltd., Switzerland
PRESENTER
(S):
Olivier Rabin, World Anti-Doping Agency (WADA), Canada Steven Elliott, Amgen Inc., United States
Mark Luttmann, Glaxosmithkline, United States
Description
Ahead of the 2012 Olympics, this session will highlight the many and varied ways in which medicines are misused for performance enhancement and address opportunities for companies to work proactively with World Anti-Doping Agency (WADA) to mitigate the risk of abuse.
Learning Objectives:
Recognize the danger of doping abuse and how this can be addressed through collaboration with World Anti-Doping Agency (WADA)
Evaluate the approaches used by different companies in proactively addressing potential for doping abuse of their medicines.
Learning Objectives:
Recognize the danger of doping abuse and how this can be addressed through collaboration with World Anti-Doping Agency (WADA)
Evaluate the approaches used by different companies in proactively addressing potential for doping abuse of their medicines.
This session is a part of:
Handout Online
